ly 117018 has been researched along with mitoxantrone in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chin, WW; Dantzig, AH; Iversen, PW; Jin, S; Krishnan, V; Lesoon, A; Moore, RE; O'Brien, KA; Peek, VL; Perry, WL; Rolfe, M; Sampath, J; Shepard, RL; Shyjan, A; Tighe, M; Williamson, M; Yaden, B | 1 |
1 other study(ies) available for ly 117018 and mitoxantrone
Article | Year |
---|---|
Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators.
Topics: Antineoplastic Agents; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Estrogen Receptor beta; Etoposide; Female; Humans; Mitoxantrone; Ovarian Neoplasms; Pyrrolidines; RNA Splicing; RNA Splicing Factors; RNA-Binding Proteins; RNA, Catalytic; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes; Transfection | 2005 |